Abbott India Limited (ABBOTINDIA) AI Stock Analysis

Top Page

Abbott India Limited

(NSE:ABBOTINDIA)

Select Model

Rating:73Outperform

Price Target:INR 30,191.00▲(17.96% Upside)

Action:reiterated

Date:08/17/26

The score is driven primarily by strong financial performance (solid growth, high profitability, very low leverage, and strong cash conversion). This is tempered by a mixed technical picture (near-term softness with neutral momentum) and a relatively high valuation (P/E ~37), only partly offset by the dividend yield.

Positive Factors

Steady Revenue GrowthThe multi-year revenue increase indicates sustained demand for Abbott India’s branded medicines and healthcare products, supported by its broad therapy portfolio and established distribution and prescription-led channel presence.

Negative Factors

Gross Margin CompressionThe sharp margin decline may reflect an unfavorable product mix, higher input costs or pricing pressure. If persistent, it could reduce the quality and durability of earnings despite strong reported net profitability.

Abbott India Limited (ABBOTINDIA) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 544.73B
Dividend Yield: 2.05%
Average Volume (3M): 1,864
Price to Earnings (P/E): 33.7
Beta (1Y): 0.41
Revenue Growth: 6.29%
EPS Growth: 11.18%
Country: India
Employees: 3,749
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Abbott India Limited Business Overview & Revenue Model

Company Description

Abbott India Limited is a pharmaceutical enterprise that conducts its operations across India. The company provides an extensive portfolio of medicinal products designed for a broad spectrum of therapeutic areas, including women's health, digestive c...

How the Company Makes Money

Abbott India Limited primarily makes money by selling pharmaceutical and healthcare products in India, with revenue largely recognized from the sale of finished formulations (branded medicines and related healthcare products) to trade channels (e.g.,...

Abbott India Limited Financial Statement Overview

Summary

High-quality fundamentals: steady revenue growth (₹43.1B to ₹69.3B from 2021–2026), strong and improving net margin (~16.0% to ~22.4%), exceptionally low leverage (debt-to-equity ~0.008 in 2026), and strong cash conversion (FCF ~97.6% of net income in 2026). Key risks are the sharp 2026 gross margin compression (~45.2% to ~36.2%) and volatility in year-to-year FCF growth.

Income Statement

86Very Positive

Balance Sheet

92Very Positive

Cash Flow

88Very Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	69.29B	69.29B	64.07B	58.47B	53.47B	49.10B
Gross Profit	30.71B	25.10B	28.96B	26.15B	23.63B	22.43B
EBITDA	21.80B	21.74B	19.70B	17.01B	13.60B	11.65B
Net Income	15.52B	15.52B	14.14B	12.01B	9.49B	7.99B
Balance Sheet
Total Assets	65.02B	65.02B	59.17B	51.93B	45.56B	42.24B
Cash, Cash Equivalents and Short-Term Investments	23.86B	22.55B	31.13B	21.18B	19.22B	27.35B
Total Debt	1.72B	1.72B	1.97B	832.30M	1.13B	1.52B
Total Liabilities	17.28B	17.28B	16.84B	14.95B	13.67B	14.04B
Stockholders Equity	47.74B	47.74B	42.33B	36.99B	31.89B	28.20B
Cash Flow
Free Cash Flow	5.05B	16.63B	9.59B	11.64B	8.59B	9.04B
Operating Cash Flow	5.22B	17.04B	10.12B	12.13B	8.93B	9.48B
Investing Cash Flow	5.48B	-7.56B	1.82B	-4.16B	-1.48B	-3.96B
Financing Cash Flow	-10.40B	-10.66B	-9.25B	-7.45B	-6.39B	-6.37B

Abbott India Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price25593.30

Price Trends

50DMA26151.97Negative

100DMA26390.91Negative

200DMA26263.12Negative

Market Momentum

MACD-187.96Negative

RSI45.16Neutral

STOCH73.46Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ABBOTINDIA, the sentiment is Negative. The current price of 25593.30 is below the 20-day moving average (MA) of 25886.04, below the 50-day MA of 26151.97, and below the 200-day MA of 26263.12, indicating a bearish trend. The MACD of -187.96 indicates Negative momentum. The RSI at 45.16 is Neutral, neither overbought nor oversold. The STOCH value of 73.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ABBOTINDIA.

Abbott India Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ABBOTINDIA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:CIPLA	79Outperform	INR 1.11T	38.44	―	2.10%	-0.74%	-46.77%
IN:ABBOTINDIA	73Outperform	INR 543.84B	33.74	―	2.05%	6.29%	11.18%
IN:SANOFI	70Outperform	INR 73.80B	20.24	―	3.84%	-5.74%	2.30%
IN:GLAXO	68Neutral	INR 420.73B	39.56	―	2.29%	5.75%	12.41%
IN:PFIZER	67Neutral	INR 168.67B	22.95	―	2.03%	10.69%	-9.09%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:ABBOTINDIA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ABBOTINDIA	Abbott India Limited	25593.30	-2826.16	-9.94%
IN:CIPLA	Cipla Ltd	1380.00	-117.54	-7.85%
IN:GLAXO	GlaxoSmithKline Pharmaceuticals Limited	2483.55	-135.33	-5.17%
IN:PFIZER	PFIZER LIMITED	3687.05	-1407.11	-27.62%
IN:SANOFI	Sanofi India Limited	3204.40	-1441.42	-31.03%
IN:SANOFICONR	Sanofi Consumer Healthcare India Limited	3435.05	-1279.73	-27.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026

Abbott India Limited AI Stock Analysis

Top Page